Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2015/424031 http://scihub22266oqcxt.onion/10.1155/2015/424031 C4503583!4503583!26221593     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomed+Res+Int 2015 ; 2015 (ä): ä Nephropedia Template TP {{tp|p=26221593|t=2015. Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management |pdf=|usr=}}{{26221593}} gab.com Text Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management JO: Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=26221593 #FOAvip Atrial fibrillation continues to be a significant source of morbidity and mortality worldwide. Effective anticoagulation remains the cornerstone of outpatient and inpatient treatment. The use of the new generation of anticoagulants (NOACs) continues to grow. Recently published data indicate their cost-effectiveness and overall safety in stroke prevention; compared to vitamin K antagonists, they can be prescribed in fixed doses for long-term therapy without the need for coagulation monitoring. Both United States and European Guidelines recommend NOACs for stroke prevention in patients with atrial fibrillation. This review discusses each of the NOACs, along with their efficacy and safety data. It explores the most recent guidelines regarding their perioperative use in atrial fibrillation patients. It also discusses bleeding complications, perioperative management, and reversal agents. Twit Text FOAVip Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management ????Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=26221593 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26221593 #FOAvip English Wikipedia <ref>{{Cite pmid|26221593}}</ref> Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management #MMPMID26221593 Shamoun F; Obeid H; Ramakrishna H Biomed Res Int 2015[]; 2015 (ä): ä PMID26221593show ga Atrial fibrillation continues to be a significant source of morbidity and mortality worldwide. Effective anticoagulation remains the cornerstone of outpatient and inpatient treatment. The use of the new generation of anticoagulants (NOACs) continues to grow. Recently published data indicate their cost-effectiveness and overall safety in stroke prevention; compared to vitamin K antagonists, they can be prescribed in fixed doses for long-term therapy without the need for coagulation monitoring. Both United States and European Guidelines recommend NOACs for stroke prevention in patients with atrial fibrillation. This review discusses each of the NOACs, along with their efficacy and safety data. It explores the most recent guidelines regarding their perioperative use in atrial fibrillation patients. It also discusses bleeding complications, perioperative management, and reversal agents. äNovel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and (epmc).pdf DeepDyve Pubget Overpricing